Adults 20 to 74, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline in Total Clamp Disposition Index (cDI)Primary· Baseline, Week 28
cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Least squares (LS) mean was determined by analysis of covariance (ANCOVA) model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
1.9
± 0.16
Semaglutide 1 mg
1.1
± 0.10
Placebo
0.0
± 0.03
Change From Baseline in Fasting GlucoseSecondary· Baseline, Week 28
Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. Fasting glucose was measured prior to standardized mixed-meal tolerance tests (sMMTT). LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
-51.4
± 2.30
Semaglutide 1 mg
-42.4
± 2.22
Placebo
-4.3
± 2.98
Change From Baseline in Postmeal GlucoseSecondary· Baseline, Week 28
Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares) and ANOVA model for baseline measures: Variable = Treatment (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
-17414.0
± 726.02
Semaglutide 1 mg
14236.9
± 709.53
Placebo
459.2
± 947.50
Change From Baseline in Hemoglobin A1c (HbA1c)Secondary· Baseline, Week 28
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by mixed model repeated measures; (MMRM) model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
2.05
± 0.079
Semaglutide 1 mg
-1.64
± 0.078
Placebo
0.29
± 0.101
Change From Baseline in Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)Secondary· Baseline and Week 28
Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min) will be determined from C-peptide concentrations using the deconvolution technique. LS mean was determined by ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
388.6
± 20.17
Semaglutide 1 mg
286.6
± 15.82
Placebo
7.4
± 7.15
Change From Baseline in Hyperinsulinemic Euglycemic Clamp M-valueSecondary· Baseline, Week 28
Hyperinsulinemic euglycemic clamp M-value is calculated from glucose infusion rate (GIR) over the last 30 minutes, corresponding to steady-state (+150 to +180 minutes), corrected for urine loss and space. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
19.2
± 1.93
Semaglutide 1 mg
10.7
± 1.99
Placebo
-0.6
± 2.53
Change From Baseline in Glucagon Concentration at FastingSecondary· Baseline and Week 28
Glucagon concentration was measured prior to sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
-3.6
± 0.55
Semaglutide 1 mg
-2.8
± 0.55
Placebo
0.8
± 0.75
Change From Baseline in Glucagon Concentration at PostmealSecondary· Baseline and Week 28
Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
-843.6
± 86.26
Semaglutide 1 mg
-502.0
± 87.33
Placebo
-205.9
± 116.31
Change From Baseline in Food Intake During Ad Libitum MealSecondary· Baseline, Week 28
Ad libitum meal served buffet-style. Food intake was recorded during a 45 minute period. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
Group
Value
95% CI
Tirzepatide 15 mg
-348.4
± 34.59
Semaglutide 1 mg
-284.1
± 33.94
Placebo
-38.6
± 45.17
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to Week 32.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
· Phase 2
· not yet recruiting
NCT06732245 — Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
· Phase 2
· not yet recruiting
NCT07349641 — A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia
· Phase 2
· not yet recruiting
NCT07265752 — Tirzepatide for the Treatment of Cannabis Use Disorder
· Phase 2
· not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation
· NA
· not yet recruiting
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2
· Phase 2
· recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part
· recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use
· NA
· recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
· Phase 1
· recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0
· recruiting
Other Eli Lilly and Company trials
Trials by the same sponsor.
NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
· Phase 2
· not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
· Phase 2
· not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants
· Phase 1
· completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
· Phase 1
· completed
NCT07030127 — A Study of LY3985863 in Healthy Participants
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 20 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951753.